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Abstract
Background: Cystic neoplasms of the pancreas are less common than solid tumors, and portend
a better prognosis. They can be divided into serous and mucinous subtypes, with the former
behaving less aggressively and generally considered benign. Of the serous neoplasms, serous
microcystic adenoma is the most common. An extremely rare solid variant of serous microcystic
adenoma lacking secretory capability has been described. Herein, we present the fourth described
case of this solid variant and review the literature.
Case presentation: We present a case of a 62 year-old man with a history of abdominal pain,
who on CT scan was found to have a solid mass at the junction of the head and body of the
pancreas. The patient was offered resection for diagnosis and treatment, and subsequently
underwent distal pancreatectomy and splenectomy. Based on gross pathology, histology and
immunohistochemistry, the mass was determined to be a solid serous microcystic adenoma.
Conclusion: Solid serous microcystic adenoma shows similar histologic and immunohistologic
features to its classic cystic counterpart, but lacks any secretory functionality. It appears to behave
in a benign manner, and as such, surgical resection is curative for patients with this tumor.
Furthermore, until more cases of solid SMA are identified to further elucidate its natural history
and improve the reliability of preoperative diagnosis, surgical resection of this solid pancreatic
tumor should be considered standard therapy in order to exclude malignancy.
Background
Tumors of the pancreas generally portend a poor progno-
sis, the majority of these being highly malignant ductal
adenocarcinomas [1]. Much less common are the pancre-
atic cystic neoplasms, which include serous and mucinous
subtypes, among others. Together these comprise only 1–
2% of all pancreatic exocrine tumors [2]. Architecturally,
the serous cystic tumors are comprised of cuboidal cells
arising from the pancreatic ductal epithelium, and having
clear, glycogen-rich cytoplasm with small, central nuclei
[1]. An important clinical distinction is that the serous
neoplasms tend to be benign, whereas their mucin pro-
ducing counterparts may go on to malignancy [3]. Excep-
tions to this include the few cases of serous
adenocarcinoma that have been reported [4-6]; these
serous adenocarcinomas can show both direct spread [7]
and distant metastases [6]. Serous pancreatic neoplasms
can be identified by the pattern of histochemical (periodic
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acid-schiff [PAS] and mucin) and immunohistochemical
staining. They show positive staining for PAS that is dia-
stase sensitive. Typically, they stain positive for various
cytokeratins, neuron-specific enolase (NSE), α-inhibin,
MUC-1 and MUC-6 [1,8], and negative for α-smooth
muscle actin, S-100 protein, carcinoembryonic antigen
(CEA), chromogranin and synaptophysin [8].
Serous microcystic cystadenoma (SMA) is the most com-
monly encountered of the serous cystic neoplasms. On
gross examination, SMA typically is a well circumscribed,
round to ovoid lesion with a spongy consistency [7].
Often there is a central fibrous scar in a stellate pattern [3].
Surrounding the scar are innumerable small cysts contain-
ing a thin, clear fluid [3]. These lesions are most often sin-
gle, although multifocal SMA has been reported [2]. An
oligocystic form has also been described which, in con-
trast to SMA, contains only a few large cystic spaces [9].
A rare solid variant of SMA has been described in three
previous cases [1,10,11]. Although the cytological and
architectural features are largely the same, these tumors
are distinguished from the classic SMA by their lack of
fluid filled cysts, which gives them a more compact struc-
ture [10]. The first reported case of solid SMA was discov-
ered in a 70 year-old female with a history of diffuse
abdominal pain. She was found to have a 4 cm well-
defined, solid mass in the tail of the pancreas on CT,
which was then resected by distal pancreatectomy. The
second case was a 2.5 cm solid tumor in the pancreatic
head of a 50 year-old male patient, which was well cir-
cumscribed and separate from a concurrent pancreatic
ductal adenocarcinoma. The third, a 4 cm solid mass at
the junction of the pancreatic head and body, was found
incidentally on workup for an unrelated problem in a 69
year-old male. Both of these more recent cases were
resected by pylorus-preserving pancreaticoduodenec-
tomy. Herein we report a fourth case of solid serous
microcystic adenoma of the pancreas.
Case presentation
Clinical course
A 62 year-old man with a several month history of
abdominal pain was referred to The Ohio State University
Medical Center in June, 2006. His past medical history
was significant for hypertension, arthritis and chronic
back pain. On computed tomography scan he was found
to have a heterogeneously enhancing solid mass at the
junction of the head and body of the pancreas (Figure 1).
Based on initial imaging, the differential diagnosis
included pancreatic ductal adenocarcinoma, pancreatic
endocrine tumor, solid pseudopapillary tumor, and met-
astatic carcinoma.
The patient was offered resection for diagnosis and defin-
itive therapy. After undergoing diagnostic laparoscopy to
rule out carcinomatosis in the peritoneal cavity, a distal
pancreatectomy with splenectomy was completed.
The patient tolerated the procedure well and was dis-
charged after an uneventful hospital stay.
Pathological findings
Gross examination of the resected specimen demon-
strated a 4.2 × 2.5 × 2.0 cm solid, well circumscribed, non-
encapsulated mass adjacent to the pancreatic duct (Figure
2). The cut surface of the tumor contained thick fibrous
bands without hemorrhage or necrosis. The surrounding
pancreatic parenchyma was noted to be grossly unremark-
able, and surgical margins were negative. On hematoxylin
and eosin stain, the architecture of the mass was solid
with cells arranged in nests, acini and trabeculae, sepa-
rated by thick, hypocellular fibrous bands (Figure 3A).
Rare small cystic areas were seen microscopically (less
than 1% of the tumor). The tumor was homogenous and
consisted of polygonal cells with centrally placed small,
round to ovoid nuclei (Figure 3B). No mitoses or cellular
atypia were noted. The cells contained abundant clear
cytoplasm which was PAS positive and diastase sensitive
suggesting the presence of glycogen (Figure 4). No vascu-
lar or perineural invasion was seen.
Mucicarmine stain was negative. Immunohistochemistry
showed positive staining for cytokeratin 7 (CK7), cytoker-
atin 19 (CK19), neuron-specific enolase (NSE), α-inhibin
and calponin; and negative staining for vimentin, α1-anti-
trypsin (A1AT), synaptophysin, carcinoembryonic anti-
gen (CEA), renal cell carcinoma stain (RCC), CD10, S-100
protein, and smooth muscle actin. These findings support
the final diagnosis of solid microcystic adenoma.
Discussion
For a solid, clear cell tumor in the pancreas, the differen-
tial diagnosis includes neuroendocrine tumors, solid
pseudopapillary tumor, ductal adenocarcinoma, acinar
cell carcinoma, solid serous microcystic adenoma, and
metastatic clear cell carcinoma of renal, myoepithelial or
other origin. A diagnosis of solid SMA was made in this
case after considering gross pathology, histology and
immunostaining characteristics.
The previous cases of solid SMA were all well-circum-
scribed, spherical masses ranging in size from 2.5–4.0 cm.
Our specimen shared these characteristics and was
approximately the same size, with a maximal dimension
of 4.2 cm. Histologically our case is virtually identical. All
four have had the same general solid architecture: thick
fibrous bands separating glandular structures composedWorld Journal of Surgical Oncology 2007, 5:26 http://www.wjso.com/content/5/1/26
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of clear, cuboidal cells with central nuclei and abundant
glycogen.
Further evidence supporting the diagnosis came from
immunohistochemical studies. Positive staining for CK7,
CK19 and NSE is consistent with the other solid SMA
cases, and these markers are generally present in serous
microcystic adenomas [10]. The absence of chromogranin
and synaptophysin staining argues against a neuroendo-
crine tumor. Solid pseudopapillary tumor is also unlikely
given negative staining for vimentin and A1AT and diffuse
strong staining with several cytokeratins.
Renal and myoepithelial cell carcinomas can metastasize
to the pancreas, and may be difficult to distinguish from a
primary pancreatic cancer [12]. This tumor showed nega-
tive staining for RCC, vimentin, CD10 and smooth mus-
cle actin, which does not support a metastatic lesion with
renal or myoepithelial cell origin. Interestingly though,
staining for calponin was positive, something not evalu-
ated in the previous cases of SMA.
CT scan of the abdomen with contrast Figure 1
CT scan of the abdomen with contrast. A heterogeneously enhancing, solid mass can be identified at the junction of the head 
and body of the pancreas (arrow).World Journal of Surgical Oncology 2007, 5:26 http://www.wjso.com/content/5/1/26
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Distal pancreas, gross specimen Figure 2
Distal pancreas, gross specimen. An ovoid, well circumscribed, solid mass measuring 4.2 × 2.5 × 2.0 cm is seen adjacent to the 
pancreatic duct and extending to the periphery of the specimen (arrow).
Hematoxylin and eosin stain Figure 3
Hematoxylin and eosin stain. (A) Low-power magnification (10×) shows irregular trabeculae and glandular structures, sepa-
rated by hypocellular fibrous bands. Note the absence of cystic spaces within the glands. (B) Higher magnification (40×) dem-
onstrates a homogenous population of polygonal cells with clear cytoplasm and small, central, round nuclei.World Journal of Surgical Oncology 2007, 5:26 http://www.wjso.com/content/5/1/26
Page 5 of 6
(page number not for citation purposes)
Conclusion
Solid tumors of the pancreas are typically associated with
malignancy, whereas cystic tumors more often tend to be
benign [11]. Given the histologic and immunohistochem-
ical characteristics of solid serous microcystic adenoma, it
is likely more related to the cystic tumors than to the solid
ones, as its gross pathology might suggest. Clinically this
holds true as well, as the three previous cases have all been
considered benign lesions without evidence of local
spread or metastasis. Given the benign nature of solid
SMA, surgical resection most likely represents definitive
treatment and cure. In addition, resection is indicated due
to the difficulty in diagnosing solid SMA preoperatively.
Most solid tumors of the pancreas should be resected due
to their high malignant potential, and since a diagnosis of
solid SMA will likely not be made until histologic and
immunohistochemical analyses are completed, it should
be treated as a potentially malignant lesion as well. Thus,
until more cases of solid SMA are identified to further elu-
cidate its natural history and improve the reliability of
preoperative diagnosis, surgical resection should still be
considered standard therapy in suitable patients to
exclude malignancy.
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